Our study also suggests that the difference in NDRG2 expression in tumor cells may result in differential responses to micro-environmental stimuli and may influence tumor progression and patient prognosis, which suggests that NDRG2 may be developed as a clinically relevant molecular biomarker that may potentially be used in cancer diagnosis and therapy. This evidence concerns the gene NDRG2 and neoplasm.